Seegenschmiedt M H, Keilholz L, Martus P, Goldmann A, Wölfel R, Henning F, Sauer R
Department of Radiation Oncology, University Erlangen-Nürnberg, Erlangen, Germany.
Int J Radiat Oncol Biol Phys. 1997 Aug 1;39(1):161-71. doi: 10.1016/s0360-3016(97)00285-x.
Experimental and clinical data support effectiveness of perioperative radiotherapy to prevent heterotopic ossification after hip surgery or trauma. Since 1987, two prospectively randomized trials were performed in patients with high-risk factors to develop heterotopic ossification: the first (HOP 1) to assess the prophylactic efficacy of postoperative low vs. medium dose radiotherapy, and the second (HOP 2) to assess the prophylactic efficacy of pre vs. postoperative radiotherapy.
410 patients with high risk to develop heterotopic ossifications about the hip following hip surgery were recruited. Between June 1987 and June 1992, 249 patients were randomized in HOP 1 to postoperative "low dose" (5 x 2 Gy; total: 10 Gy) or "medium dose" (5 x 3.5 Gy; total: 17.5 Gy) radiotherapy. Between July 1992 and December 1995, 161 patients were randomized in HOP 2 to either 1 x 7 Gy preoperatively (< or = 4 h before surgery) or 5 x 3.5 Gy (total: 17.5 Gy) postoperatively (< or = 96 h after surgery). With exception of age and type of implant (cemented vs. uncemented prosthesis) all confounding patient variables (gender, prior surgery) and predisposing risk factors were similarly distributed between both trials and treatment arms. Portals encompassed the periacetabular and intertrochanteric soft tissues. Radiographs were obtained prior and immediately after surgery and at least 6 months after surgery to assess the extent of ectopic bone formation about the hip. Modified Brooker grading was used to score the extent of heterotopic ossification. Harris scoring was applied to evaluate the functional hip status. If the scores decreased from immediate post or preoperative status, respectively, to the last follow-up, radiological or functional failures were assumed.
Effective prophylaxis was achieved in 227 (91%) hips of HOP 1 and in 142 (88%) of HOP 2. In HOP 1, 15 (11%) radiological failures were observed in the low-dose group compared to 7 (6%) in the medium dose group (p > 0.05). In HOP 2, 4 (5%) radiological failures were observed in the postoperative and 11 (19%) in the preoperative group (p < 0.05). Subgroup analysis of the preoperative group revealed that the highest failure rate occurred in patients with prophylactic radiotherapy prior to removal of ipsilateral Brooker Grade III and IV ossification (39%) (p < 0.001), while all other patients in the preoperative group had a failure rate that was comparable to postoperative treatment groups. In multivariate logistic regression analysis the number of high-risk factors for development of heterotopic ossification (p = 0.03) and the time to RT initiation (p = 0.05) were independent prognostic factors in the HOP 1 study. For the HOP 2 study, the multivariate logistic regression analysis revealed the number of high-risk factors for development of heterotopic ossification (p = 0.003), the preoperative HO grade (p = 0.001) and the RT dose concept (p = 0.05) as independent prognostic factors. Other factors including type of implant (cemented vs. uncemented) did not affect the prophylactic efficacy of radiotherapy. There were no increased intra- and postoperative complications seen in the preoperative group, and no long-term complications were observed in both HOP studies. For functional failures (decrease of Harris score) no statistically prognostic factors were found. There were less functional failures in HOP 1 (18 = 7%) than in HOP 2 (23 = 14%, but this difference was not statistically significant. Only patients with high Brooker Grade III and IV at last FU achieved a lower Harris score than those with low Brooker Grade 0, I and II (p < 0.05).
With the exception of a small subgroup of patients with ipsilateral high Brooker Grade III and IV, pre- and postoperative radiotherapy are equally effective to prevent heterotopic ossification about the hip after hip surgery and total hip arthroplasty. Fractionated medium dose radiotherapy resulted in the low
实验和临床数据支持围手术期放疗对预防髋关节手术或创伤后异位骨化的有效性。自1987年以来,针对有发生异位骨化高危因素的患者进行了两项前瞻性随机试验:第一项(HOP 1)评估术后低剂量与中等剂量放疗的预防效果,第二项(HOP 2)评估术前与术后放疗的预防效果。
招募了410例髋关节手术后有发生髋关节周围异位骨化高危风险的患者。1987年6月至1992年6月,249例患者在HOP 1中被随机分为术后“低剂量”(5×2 Gy;总计10 Gy)或“中等剂量”(5×3.5 Gy;总计17.5 Gy)放疗组。1992年7月至1995年12月,161例患者在HOP 2中被随机分为术前1×7 Gy(手术前≤4小时)或术后5×3.5 Gy(手术后≤96小时)放疗组。除年龄和植入物类型(骨水泥型与非骨水泥型假体)外,所有混杂的患者变量(性别、既往手术史)和诱发风险因素在两项试验及治疗组之间分布相似。射野包括髋臼周围和转子间软组织。在手术前、手术后即刻以及手术后至少6个月获取X线片,以评估髋关节周围异位骨形成的程度。采用改良布鲁克分级法对异位骨化程度进行评分。应用哈里斯评分评估髋关节功能状态。如果评分分别从术后即刻或术前状态降至最后一次随访时,则判定为放射学或功能失败。
HOP 1中227例(91%)髋关节和HOP 2中142例(88%)实现了有效预防。在HOP 1中,低剂量组观察到15例(11%)放射学失败,而中等剂量组为7例(6%)(p>0.05)。在HOP 2中,术后组观察到4例(5%)放射学失败,术前组为11例(19%)(p<0.05)。术前组的亚组分析显示,在同侧布鲁克III级和IV级骨化切除术前进行预防性放疗的患者失败率最高(39%)(p<0.001),而术前组的所有其他患者失败率与术后治疗组相当。在多因素逻辑回归分析中,异位骨化发生的高危因素数量(p = 0.03)和开始放疗的时间(p = 0.05)是HOP 1研究中的独立预后因素。对于HOP 2研究,多因素逻辑回归分析显示异位骨化发生的高危因素数量(p = 0.003)、术前异位骨化分级(p = 0.001)和放疗剂量方案(p = 0.05)为独立预后因素。其他因素,包括植入物类型(骨水泥型与非骨水泥型),不影响放疗的预防效果。术前组未观察到手术中和术后并发症增加,且在两项HOP研究中均未观察到长期并发症。对于功能失败(哈里斯评分降低),未发现有统计学意义的预后因素。HOP 1中的功能失败(18例 = 7%)少于HOP 2(23例 = 14%),但这种差异无统计学意义。仅最后随访时布鲁克III级和IV级高的患者哈里斯评分低于布鲁克0级、I级和II级低的患者(p<0.05)。
除一小部分同侧布鲁克III级和IV级高的患者亚组外,术前和术后放疗在预防髋关节手术和全髋关节置换术后髋关节周围异位骨化方面同样有效。分次中等剂量放疗导致较低……